title: Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
abstract: OBJECTIVE
  Preliminary data have shown that delayed release oral mesalamine (Asacol) dosed at 4.8 g/day provided additional efficacy benefit compared to 1.6 g/day in patients with mildly to moderately active ulcerative colitis. Additionally, Asacol dosed at 2.4 g/day has been proved to be more effective than 1.6 g/day. Whether 4.8 g/day of mesalamine (dosed with an investigational 800 mg tablet) is more effective than Asacol 2.4 g/day (dosed with a 400 mg tablet) in patients with moderately active ulcerative colitis is unknown.
  
  
  METHODS
  A randomized, double-blind, controlled trial (ASCEND II) was conducted to evaluate the efficacy of 4.8 g/day of mesalamine in adults with active ulcerative colitis. Three hundred eighty-six patients with mild to moderate ulcerative colitis were randomized for treatment with mesalamine 2.4 g/day (400 mg tablet) or 4.8 g/day (800 mg tablet) for 6 wk. The primary efficacy population was 268 patients with moderately active ulcerative colitis treated with 2.4 g/day (n = 139) or 4.8 g/day (n = 129). The primary endpoint was the proportion of patients in each treatment group that achieved overall improvement ("treatment success," defined as either complete remission or a clinical response to therapy) from baseline at week 6.
  
  
  RESULTS
  Seventy-two percent of patients receiving 4.8 g/day of mesalamine for moderate ulcerative colitis (89/124 patients) achieved treatment success at week 6, compared with 59% of those who received 2.4 g/day (77/130 patients) (p= 0.036). Both regimens were well tolerated. Adverse events and clinically significant changes in laboratory results were similar in both treatment groups.
  
  
  CONCLUSIONS
  Patients with moderately active ulcerative colitis treated with 4.8 g/day of mesalamine (800 mg tablet) are significantly more likely to achieve overall improvement at 6 wk compared to patients treated with 2.4 g/day.
authors.affiliation: Division of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois 60637, USA.
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Hanauer
authors.forename: William J
authors.initials: WJ
authors.lastname: Sandborn
authors.forename: Asher
authors.initials: A
authors.lastname: Kornbluth
authors.forename: Seymour
authors.initials: S
authors.lastname: Katz
authors.forename: Michael
authors.initials: M
authors.lastname: Safdi
authors.forename: Scott
authors.initials: S
authors.lastname: Woogen
authors.forename: Gino
authors.initials: G
authors.lastname: Regalli
authors.forename: Chyon
authors.initials: C
authors.lastname: Yeh
authors.forename: Nancy
authors.initials: N
authors.lastname: Smith-Hall
authors.forename: Funmilay
authors.initials: F
authors.lastname: Ajayi
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D003093:Colitis, Ulcerative / Q000145:classification / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D008875:Middle Aged; D010919:Placebos; D012008:Recurrence; D012074:Remission Induction; D012449:Safety; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D010919:Placebos; D019804:Mesalamine